On May 6, 2020, Laurent Pharmaceuticals announced that it has obtained the approval from Health Canada to initiate RESOLUTION, a Phase 2 randomized placebo-controlled trial testing once-a-day oral LAU-7b as a potential drug candidate to help combat the COVID-19 disease.

The trial was planned to start in multiple hospitals in Canada with approximatively 200 hospitalized COVID-19 patients enrolled for a treatment duration of 14 days.